News and Press Releases

Contact Veristat Now


Request A Proposal

Contact Us

Veristat Launches Strategic Resourcing to Build Greater Flexibility in its Suite of Engagement Models

Providing sponsors expert staff to accelerate milestones and support study success

 

Read More

Veristat Expands its Expertise and Scale across Biopharma and Medtech

Acquires Swiss-based multi-disciplinary consultancy SFL (Solutions for Life Sciences) to accelerate the development of and access to innovative treatments

 

Read More

Veristat Appoints Joe Scott as Chief Financial Officer

Accomplished Financial Executive to Drive Company’s Next Phase of Growth

 

Read More

Veristat Supported Marketing Applications for 12% of all FDA Novel Drug Approvals in 2021

Bridging the Gap between Trial and Treatment by Supporting the Approval of Several Novel Therapies for Rare Diseases

 

Read More

Veristat Strengthens Regulatory Capabilities Across Europe and UK

Acquires Drug Development and Regulation (DDR), a
regulatory consultancy led by former senior officer at
European Medicines Agency (EMA)

 

Read More

Veristat Appoints Colleen Pelton Chief Talent Officer

Global Talent Executive to Advance Company’s Commitment to a
Best-in-class Workforce

 

Read More

Veristat Announces New Investment Partner—WindRose Health Investors

Recapitalization Will Accelerate Strategic Growth to Help Sponsors Save and Improve the Lives of Patients

 

Read More

Veristat Congratulates Origin Biosciences for FDA Approval

Veristat Congratulates Origin Biosciences for FDA Approval of Nulibry during the Week of Rare Disease Day 2021


Veristat Supported the NDA and Celebrates this Milestone Achievement for Children and their Families Fighting This Rare Disease



SOUTHBOROUGH, MA – 8 March 2021 –Veristat, a scientific-minded, global clinical research organization (CRO), today congratulated Origin Biosciences for their FDA approval of Nulibry (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. This rare disease product received FDA approval on Friday, 26 February 2021, during the week when the world celebrated #RareDiseaseDay2021.

Read More

Veristat Expands Biometrics Capabilities by Acquiring SQN Clinical

Builds on a shared pedigree of data management, statistics and programming excellence across all phases of clinical trials

SOUTHBOROUGH, MA – February 25, 2021 – Veristat, a scientific-minded global clinical research organization (CRO), announced today the expansion of its biometrics capacities by acquiring SQN Clinical, a market-leader in the healthcare arena and one of the largest data focused specialty contract research companies in Europe. 

Read More

Veristat Supported Marketing Applications for 10% of all FDA Novel Drug Approvals in 2020

Strengthening its Track Record of Successful Client Regulatory Approval Outcomes

SOUTHBOROUGH, MA – January 14, 2021 – Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)[i], and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe.

Read More